Daejeon, South Korea

Eun-Ju Ryu



 

Average Co-Inventor Count = 8.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Eun-Ju Ryu: Innovator in Pharmaceutical Compounds

Introduction

Eun-Ju Ryu is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target central nervous system disorders. With a total of 4 patents to his name, Ryu's work is paving the way for new treatments in mental health.

Latest Patents

Ryu's latest patents focus on 3 or 4-substituted piperidine compounds. These compounds are disclosed as racemic or enantiomerically enriched forms, represented by a specific structural formula. The patents also cover their isomers and pharmaceutically acceptable salts. The pharmaceutical compositions containing these compounds are particularly useful for treating diseases of the central nervous system, including depression, anxiety, and pain disorders.

Career Highlights

Eun-Ju Ryu is currently associated with Sk Biopharmaceuticals Co., Ltd. His work at this company has been instrumental in advancing research and development in the pharmaceutical sector. Ryu's innovative approach and dedication to improving mental health treatments have garnered attention in the scientific community.

Collaborations

Ryu collaborates with several talented individuals in his field, including Chun-Eung Park and Yong-Je Shin. These collaborations enhance the research efforts and contribute to the successful development of new pharmaceutical solutions.

Conclusion

Eun-Ju Ryu's contributions to the field of pharmaceuticals, particularly through his innovative piperidine compounds, highlight his role as a key inventor in addressing central nervous system disorders. His ongoing work promises to make a significant impact on mental health treatment options in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…